Early lethality and neuronal proteinopathy in mice expressing cytoplasm-targeted FUS that lacks the RNA recognition motif

Mutations to the RNA binding protein, fused in sarcoma (FUS) occur in ∼5% of familial ALS and FUS-positive cytoplasmic inclusions are commonly observed in these patients. Altered RNA metabolism is increasingly implicated in ALS, yet it is not understood how the specificity with which FUS interacts with RNA in the cytoplasm can affect its aggregation in vivo. To further understand this, we expressed, in mice, a form of FUS (FUS ΔRRMcyt) that lacked the RNA recognition motif (RRM), thought to impart specificity to FUS-RNA interactions, and carried an ALS-associated point mutation, R522G, retaining the protein in the cytoplasm. Here we report the phenotype and results of histological assessment of the brain of transgenic mice expressing this isoform of FUS. Results demonstrated that neuronal expression of FUS ΔRRMcyt caused early lethality often preceded by severe tremor. Large FUS-positive cytoplasmic inclusions were found in many brain neurons; however, neither neuronal loss nor neuroinflammatory response was observed. In conclusion, the extensive FUS proteinopathy and severe phenotype of these mice suggests that affecting the interactions of FUS with RNA in vivo may augment its aggregation in the neuronal cytoplasm and the severity of disease processes.

[1]  N. Seyfried,et al.  FUS is Phosphorylated by DNA-PK and Accumulates in the Cytoplasm after DNA Damage , 2014, The Journal of Neuroscience.

[2]  V. Buchman,et al.  Multistep process of FUS aggregation in the cell cytoplasm involves RNA-dependent and RNA-independent mechanisms , 2014, Human molecular genetics.

[3]  Li-Huei Tsai,et al.  ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects. , 2014, The Journal of clinical investigation.

[4]  C. Troakes,et al.  Compromised paraspeckle formation as a pathogenic factor in FUSopathies , 2013, Human molecular genetics.

[5]  T. Shelkovnikova.  Modelling FUSopathies: focus on protein aggregation. , 2013, Biochemical Society transactions.

[6]  G. Hicks,et al.  ALS-Associated FUS Mutations Result in Compromised FUS Alternative Splicing and Autoregulation , 2013, PLoS genetics.

[7]  V. Buchman,et al.  Recruitment into stress granules prevents irreversible aggregation of FUS protein mislocalized to the cytoplasm , 2013, Cell cycle.

[8]  D. Cleveland,et al.  Converging Mechanisms in ALS and FTD: Disrupted RNA and Protein Homeostasis , 2013, Neuron.

[9]  V. Buchman,et al.  Fused in Sarcoma (FUS) Protein Lacking Nuclear Localization Signal (NLS) and Major RNA Binding Motifs Triggers Proteinopathy and Severe Motor Phenotype in Transgenic Mice , 2013, The Journal of Biological Chemistry.

[10]  P. Alexiou,et al.  FUS regulates genes coding for RNA-binding proteins in neurons by binding to their highly conserved introns. , 2013, RNA.

[11]  Xuehui Liu,et al.  The RRM domain of human fused in sarcoma protein reveals a non-canonical nucleic acid binding site. , 2013, Biochimica et biophysica acta.

[12]  T. Cech,et al.  FUS binds the CTD of RNA polymerase II and regulates its phosphorylation at Ser2. , 2012, Genes & development.

[13]  E. Kremmer,et al.  Arginine methylation next to the PY‐NLS modulates Transportin binding and nuclear import of FUS , 2012, The EMBO journal.

[14]  V. Buchman,et al.  Selective pattern of motor system damage in gamma-synuclein transgenic mice mirrors the respective pathology in amyotrophic lateral sclerosis , 2012, Neurobiology of Disease.

[15]  Stephanie C Huelga,et al.  Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs , 2012, Nature Neuroscience.

[16]  T. Hortobágyi,et al.  Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion , 2012, Acta Neuropathologica.

[17]  C. Haass,et al.  Loss of fused in sarcoma (FUS) promotes pathological Tau splicing , 2012, EMBO reports.

[18]  Kinji Ohno,et al.  Position-dependent FUS-RNA interactions regulate alternative splicing events and transcriptions , 2012, Scientific Reports.

[19]  C. Haass,et al.  Requirements for Stress Granule Recruitment of Fused in Sarcoma (FUS) and TAR DNA-binding Protein of 43 kDa (TDP-43)* , 2012, The Journal of Biological Chemistry.

[20]  H. Bussemaker,et al.  TLS/FUS (translocated in liposarcoma/fused in sarcoma) regulates target gene transcription via single-stranded DNA response elements , 2012, Proceedings of the National Academy of Sciences.

[21]  Vincenzo Silani,et al.  TDP-43 and FUS RNA-binding Proteins Bind Distinct Sets of Cytoplasmic Messenger RNAs and Differently Regulate Their Post-transcriptional Fate in Motoneuron-like Cells* , 2012, The Journal of Biological Chemistry.

[22]  Yong-jian Liu,et al.  FUS Transgenic Rats Develop the Phenotypes of Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration , 2011, PLoS genetics.

[23]  I. Mackenzie,et al.  ALS‐associated fused in sarcoma (FUS) mutations disrupt Transportin‐mediated nuclear import , 2010, The EMBO journal.

[24]  J. Highley,et al.  Novel FUS/TLS mutations and pathology in familial and sporadic amyotrophic lateral sclerosis. , 2010, Archives of neurology.

[25]  Y. Kuroiwa,et al.  The RNA-binding protein FUS/TLS is a common aggregate-interacting protein in polyglutamine diseases , 2010, Neuroscience Research.

[26]  M. Kiernan,et al.  FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[27]  J. Manley,et al.  TLS Inhibits RNA Polymerase III Transcription , 2009, Molecular and Cellular Biology.

[28]  D. Munoz,et al.  FUS pathology in basophilic inclusion body disease , 2009, Acta Neuropathologica.

[29]  H. Kretzschmar,et al.  Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease , 2009, Acta Neuropathologica.

[30]  J. Haines,et al.  Mutations in the FUS/TLS Gene on Chromosome 16 Cause Familial Amyotrophic Lateral Sclerosis , 2009, Science.

[31]  Xun Hu,et al.  Mutations in FUS, an RNA Processing Protein, Cause Familial Amyotrophic Lateral Sclerosis Type 6 , 2009, Science.

[32]  V. Buchman,et al.  γ-Synucleinopathy: neurodegeneration associated with overexpression of the mouse protein , 2009, Human molecular genetics.

[33]  Markus Blatter,et al.  RNA recognition motifs: boring? Not quite. , 2008, Current opinion in structural biology.

[34]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[35]  C. Glass,et al.  Induced ncRNAs Allosterically Modify RNA Binding Proteins in cis to Inhibit Transcription , 2008, Nature.

[36]  Y. Kuroiwa,et al.  RNA-binding Protein TLS Is a Major Nuclear Aggregate-interacting Protein in Huntingtin Exon 1 with Expanded Polyglutamine-expressing Cells* , 2008, Journal of Biological Chemistry.

[37]  P. Anderson,et al.  Stress granules: the Tao of RNA triage. , 2008, Trends in biochemical sciences.

[38]  T. Takumi,et al.  TLS facilitates transport of mRNA encoding an actin-stabilizing protein to dendritic spines , 2005, Journal of Cell Science.

[39]  T. Takumi,et al.  Domain Architectures and Characterization of an RNA-binding Protein, TLS* , 2004, Journal of Biological Chemistry.

[40]  Nobutaka Hirokawa,et al.  Kinesin Transports RNA Isolation and Characterization of an RNA-Transporting Granule , 2004, Neuron.

[41]  C. Orvain,et al.  Identification of an RNA Binding Specificity for the Potential Splicing Factor TLS* , 2001, The Journal of Biological Chemistry.

[42]  D. Immanuel,et al.  TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. , 1997, Journal of cell science.

[43]  U. Frey,et al.  Endogenous Serine Protease Inhibitor Modulates Epileptic Activity and Hippocampal Long-Term Potentiation , 1997, The Journal of Neuroscience.

[44]  J. Abbs,et al.  Hypoglossal, trigeminal, and facial motoneuron involvement in amyotrophic lateral sclerosis , 1988, Neurology.